The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer

Journal of Ovarian Research

Volumn 7, Issue 1, 2014, Pages

  Kobayashi, Masanori ^a,f   Chiba, Asako ^b   Izawa, Hiromi ^b   Yanagida, Eri ^b   Okamoto, Masato ^c   Shimodaira, Shigetaka ^d   Yonemitsu, Yoshikazu ^e   Shibamoto, Yuta ^f   Suzuki, Noboru ^g   Nagaya, Masaki ^b,g  

^a Seren Clinic Nagoya   (Japan)

^b Seren Clinic   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SHINSHU UNIVERSITY HOSPITAL   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^g ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CA125; Dendritic cell; Immunotherapy and recurrent ovarian cancer; MUC1; WT1

Indexed keywords

ALBUMIN; DENDRITIC CELL VACCINE; LACTATE DEHYDROGENASE; PENICILLIN DERIVATIVE; PEPTIDE; PICIBANIL; ANTINEOPLASTIC AGENT; CANCER VACCINE; T LYMPHOCYTE RECEPTOR; WT1 PROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; DENDRITIC CELL; DENDRITIC CELL BASED IMMUNOTHERAPY; DISEASE CONTROL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CANCER; PRIORITY JOURNAL; RECURRENT OVARIAN CANCER; RETROSPECTIVE STUDY; SURVIVAL TIME; VACCINATION; YOUNG ADULT; CLINICAL TRIAL; FEMALE; IMMUNOLOGY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; METABOLISM; METASTASIS; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; OVARIAN NEOPLASMS; PATHOLOGY; SYNTHESIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PEPTIDES; RETROSPECTIVE STUDIES; T-CELL ANTIGEN RECEPTOR SPECIFICITY; TREATMENT OUTCOME; WT1 PROTEINS; YOUNG ADULT;

EID: 84900541220     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-7-48     Document Type: Article

References (34)

1. Cancer statistics, 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 10 29 10.3322/caac.20138 22237781
2. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U, Int J Gynaecol Obstet 2006 95 Suppl 1 161 S192 17161157
3. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ, J Clin Oncol 2002 20 1248 1259 10.1200/JCO.20.5.1248 11870167 (Pubitemid 34177431)
4. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage iii ovarian cancer: a gynecologic oncology group study. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group, J Clin Oncol 2003 21 3194 3200 10.1200/JCO.2003.02. 153 12860964 (Pubitemid 46606249)
5. Recurrent ovarian cancer: when and how to treat. Hall M, Rustin G, Curr Oncol Rep 2011 13 459 471 10.1007/s11912-011-0199-3 22045509
6. Dendritic cells and the control of immunity. Banchereau J, Steinman RM, Nature 1998 392 245 252 10.1038/32588 9521319 (Pubitemid 28155090)
7. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R, Nat Med 1996 2 52 58 10.1038/nm0196-52 8564842 (Pubitemid 26028073)
8. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH, Cancer Immunol Immunother 2012 61 629 641 10.1007/s00262-011-1081-8 22021066
9. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN, Cancer Immunol Immunother 2012 61 373 384 10.1007/s00262-011-1100-9 21927947
10. Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Koido S, Nikrui N, Ohana M, Xia J, Tanaka Y, Liu C, Durfee JK, Lerner A, Gong J, Gynecol Oncol 2005 99 462 471 10.1016/j.ygyno.2005.07.019 16137749 (Pubitemid 41502861)
11. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM, Clin Cancer Res 2009 15 5323 5337 10.1158/1078-0432. CCR-09-0737 19723653
12. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Hylander B, Repasky E, Shrikant P, Intengan M, Beck A, Driscoll D, Singhal P, Lele S, Odunsi K, Gynecol Oncol 2006 101 12 17 10.1016/j.ygyno.2005.09.052 16263157
13. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H, Aozasa K, Mod Pathol 2006 19 804 814 16547468 (Pubitemid 43780450)
14. Structure, function and gene expression of epithelial mucins. Seregni E, Botti C, Massaron S, Lombardo C, Capobianco A, Bogni A, Bombardieri E, Tumori 1997 83 625 632 9267478 (Pubitemid 27325971)
15. Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Fan XN, Karsten U, Goletz S, Cao Y, Pathol Res Pract 2010 206 585 589 10.1016/j.prp.2010.03.006 20400237
16. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, Li Y, Gynecol Oncol 2007 105 695 702 10.1016/j.ygyno.2007.02.004 17368732 (Pubitemid 46734194)
17. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK, Oncol Rep 2007 18 1051 1059 17914554
18. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S, Homma S, Okamoto M, Pancreas 2012 41 195 205 10.1097/MPA.0b013e31822398c6 21792083
19. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. Kobayashi M, Sakabe T, Abe H, Tanii M, Takahashi H, Chiba A, Yanagida E, Shibamoto Y, Ogasawara M, Tsujitani S, Koido S, Nagai K, Shimodaira S, Okamoto M, Yonemitsu Y, Suzuki N, Nagaya M, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT), J Gastrointest Surg 2013 17 1609 1617 10.1007/s11605-013-2286-2 23877328
20. Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. Thavaramara T, Phaloprakarn C, Tangjitgamol S, Manusirivithaya S, J Med Assoc Thai 2011 94 871 877 21774296
21. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF, J Clin Oncol 2009 27 418 425 19075271
22. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C, ICON and AGO Collaborators, Lancet 2003 361 2099 2106 12826431
23. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E, AGO-OVAR; NCIC CTG; EORTC GCG., J Clin Oncol 2006 24 4699 4707 10.1200/JCO.2006.06.0913 16966687 (Pubitemid 46630933)
24. Improved endpoints for cancer immunotherapy trials. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J, J Natl Cancer Inst 2010 102 1388 1397 10.1093/jnci/djq310 20826737
25. Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. Asher V, Lee J, Bali A, Med Oncol 2012 29 2005 2009 10.1007/s12032-011-0019-5 21735143
26. Significance of serum and peritoneal fluid lactate dehydrogenase levels in ovarian cancer. Boran N, Kayikçioǧlu F, Yalvaç S, Tulunay G, Ekinci U, Köse MF, Gynecol Obstet Invest 2000 49 272 274 10.1159/000010258 10828712 (Pubitemid 30316274)
27. Acidic pH enhances the invasive behavior of human melanoma cells. Martínez-Zaguilán R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ, Clin Exp Metastasis 1996 14 176 186 10.1007/BF00121214 8605731 (Pubitemid 26074280)
28. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Rozhin J, Sameni M, Ziegler G, Sloane BF, Cancer Res 1994 54 6517 6525 7987851
29. A study of metabolites as intermediate effectors in angiogenesis. Murray B, Wilson DJ, Angiogenesis 2001 4 71 77 10.1023/A:1016792319207 11824381 (Pubitemid 34032039)
30. Role for mitochondrial oxidants as regulators of cellular metabolism. Nemoto S, Takeda K, Yu ZX, Ferrans VJ, Finkel T, Mol Cell Biol 2000 20 7311 7318 10.1128/MCB.20.19.7311-7318.2000 10982848
31. Neutrophils: key mediators of tumour angiogenesis. Tazzyman S, Lewis CE, Murdoch C, Int J Exp Pathol 2009 90 222 231 10.1111/j.1365-2613.2009.00641.x 19563607
32. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, Wan DS, Pan ZZ, Int J Colorectal Dis 2010 25 1427 1433 10.1007/s00384-010-1052-0 20821217
33. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G, Proc Natl Acad Sci U S A 2008 105 3005 3010 10.1073/pnas.0712237105 18287062 (Pubitemid 351723658)
34. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S, Proc Natl Acad Sci U S A 2007 104 3360 3365 10.1073/pnas.0611533104 17360651 (Pubitemid 46364164)